VivoSim logs first China commercial orders for NAMkind GI toxicology, efficacy testing services - VIVS News | RalliesVivoSim logs first China commercial orders for NAMkind GI toxicology, efficacy testing services
V
VIVS• First mainland China commercial sales for NAMkind services
- VivoSim reported first commercial sales in mainland China for its NAMkind toxicology screening and GI efficacy testing services.
- Two paid engagements were signed with a Shanghai-based oncology biotech, plus a Chengdu-based pharmaceutical company, via local distributor Tekon.
- Orders cover GI toxicology screening, plus GI efficacy profiling for candidate molecules in oncology, plus other disease areas.
- The company said the two orders represent a meaningful share of contracted revenue to date, marking an Asia-Pacific expansion milestone.
